Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 2/3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Breast 5Genitourinary 3Head & Neck 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Low Anterior Resection Syndrome 1Gastroparesis 1Esophageal Neoplasms 1Esophageal Motility Disorders 1Esophageal Diseases 1Esophageal Achalasia 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 328Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 257lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Botulinum Toxins, Type A × Gastrointestinal × Clear all
NCT06721520 2026-02-25

EMPTY

The Cleveland Clinic

Phase 2/3 Recruiting
170 enrolled
Gastrointestinal

Esophageal Achalasia, Esophageal Diseases, Esophageal Motility Disorders, Gastroparesis

NCT04965311 2025-05-13

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

OHSU Knight Cancer Institute

Phase 2 Terminated
4 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02965976 2023-02-16

Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer

Roswell Park Cancer Institute

Phase 2 Completed
33 enrolled 17 charts
Gastrointestinal

Esophageal Neoplasms

NCT01822210 2018-03-09

Botulinum Toxin for Stomach Cancer Treatment

St. Olavs Hospital

Phase 2 Completed
7 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01589471 2018-02-12

The Value of Botox-A for Management of Low Anterior Resection Syndrome

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 2 Completed
23 enrolled
Gastrointestinal

Low Anterior Resection Syndrome, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡